PURR supply chain intelligence for Hyperliquid Strategies Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Hyperliquid Strategies Inc. (PURR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| GUIDANT-BIO-THERAPEUTICS-INC | GUIDANT-BIO-THERAPEUTICS-INC | 92% | In connection with the APA, the Company engaged Guidant under a transaction services agreement (the "TSA") to provide services to the Company for fees of $ 0.175 million, paid at closing of the APA. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CHARDAN-CAPITAL-MARKETS-LLC | CHARDAN-CAPITAL-MARKETS-LLC | 62% | estors, generating stockholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement. Reverse Recapitalization and Sonnet A… |
| GUIDANT-BIO-THERAPEUTICS-INC | GUIDANT-BIO-THERAPEUTICS-INC | 62% | On March 31, 2026, the Company entered into an asset purchase agreement (the "APA") with Guidant Bio Therapeutics Inc. ("Guidant"). In connection with the closing of the transactions contemplated by … |
| RORSCHACH-ADVISORS-LLC | RORSCHACH-ADVISORS-LLC | 62% | portion of the shares of Common Stock otherwise issuable to it, shares of the Company’s newly-designated Series A Preferred Stock), and (b) at the Closing the Company issued to Rorschach Advisors LLC… |
| RORSCHACH-MERGER-SONNET-MERGER-SUB-INC | RORSCHACH-MERGER-SONNET-MERGER-SUB-INC | 62% | ch consolidates the entity under ASC 810, “ Consolidations .” The Company has selected June 30 as its fiscal year end. On July 11, 2025, Sonnet BioTherapeutics Holdings, Inc. (“Sonnet”), the Company,… |
| RORSCHACH-MERGER-SUB-LLC | RORSCHACH-MERGER-SUB-LLC | 62% | the volume/activity in the current principal market declines. The Company's equity method investment is accounted for under the equity method of accounting and initially recorded at fair value but is… |
| RORSCHACH-SONNET-MERGER-SUB-INC | RORSCHACH-SONNET-MERGER-SUB-INC | 62% | the volume/activity in the current principal market declines. The Company's equity method investment is accounted for under the equity method of accounting and initially recorded at fair value but is… |
| SONNET-BIOTHERAPEUTICS-HOLDINGS-INC | SONNET-BIOTHERAPEUTICS-HOLDINGS-INC | 62% | ch consolidates the entity under ASC 810, “ Consolidations .” The Company has selected June 30 as its fiscal year end. On July 11, 2025, Sonnet BioTherapeutics Holdings, Inc. (“Sonnet”), the Company,… |
| SONNET-MERGER-SUB-INC | SONNET-MERGER-SUB-INC | 62% | ch consolidates the entity under ASC 810, “ Consolidations .” The Company has selected June 30 as its fiscal year end. On July 11, 2025, Sonnet BioTherapeutics Holdings, Inc. (“Sonnet”), the Company,… |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PURR-OWNER-D1-CAPITAL-PARTNERS-L-P | D1 Capital Partners L.P. | 90% | 13F overlay lists D1 Capital Partners L.P. as top holder; 89 tracked holders. |